Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06395103 · ClinicalTrials.gov registry record · Phase 1
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
A Phase 1 study of Diffuse Large B Cell Lymphoma and Neuroblastoma, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT06395103 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Neuroblastoma that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 90 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 19 states.
The verdict
NCT06395103, a Phase 1 study of Diffuse Large B Cell Lymphoma and Neuroblastoma, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
Conditions Studied
Interventions
- BIOLOGICAL Zilovertamab vedotin
Study Locations (20)
New York
- Memorial Sloan Kettering Cancer Center ( Site 1010) - New York
- New York Medical College ( Site 1023) - Valhalla
California
- Children's Hospital Los Angeles ( Site 1006) - Los Angeles
Colorado
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016) - Aurora
Connecticut
- Yale New Haven Hospital ( Site 1012) - New Haven
Florida
- Johns Hopkins All Children's Hospital ( Site 1025) - St. Petersburg
Iowa
- University of Iowa-Holden Comprehensive Cancer Center ( Site 1017) - Iowa City
Massachusetts
- Dana-Farber Cancer Institute ( Site 1013) - Boston
Michigan
- Corewell Health ( Site 1001) - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-08-16 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06395103
The ClinicalTrials.gov registry entry for NCT06395103 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (59% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Zilovertamab vedotin is the first listed.
NCT06395103 reports 20 study locations spanning 19 distinct geographic areas - top geographies include New York, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06395103 about?
NCT06395103 is a clinical study titled "Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)". Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma...
What is the current status of trial NCT06395103?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2024-08-16. Estimated completion is 2029-03-31.
What conditions does trial NCT06395103 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Neuroblastoma, Ewing Sarcoma, Burkitt Lymphoma, B-cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT06395103?
The interventions under investigation include: Zilovertamab vedotin (BIOLOGICAL).
Who is sponsoring clinical trial NCT06395103?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06395103 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.